Investigating how MCL1 contributes to resistance in acute myeloid leukemia treatments
Understanding the unique dependency for MCL1 in Ven/Aza resistant AML
This study is looking at how a protein called MCL1 affects acute myeloid leukemia (AML) that doesn't get better with usual treatments, to find new ways to help patients who are struggling with this tough condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10888163 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the MCL1 protein in acute myeloid leukemia (AML) that does not respond to standard treatments like venetoclax and azacitidine. The team will explore how MCL1 affects the survival and function of leukemia stem cells, which are crucial for the disease's persistence. By studying the mechanisms behind MCL1's influence on treatment resistance, the research aims to identify new therapeutic strategies that could improve outcomes for patients with resistant AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with acute myeloid leukemia who have shown resistance to venetoclax and azacitidine treatments.
Not a fit: Patients with acute myeloid leukemia who are newly diagnosed and have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia who currently have limited options.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Althoff, Mark Jordan — University of Colorado Denver
- Study coordinator: Althoff, Mark Jordan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.